Contrast Media Market (2026 - 2040)

Contrast Media Market Summary

The global contrast media market size was valued at USD 7.3 billion in 2025 and is projected to grow from USD 7.7 billion in 2026 to USD 16.1 billion by 2040, at a CAGR of 5.4% from 2026 to 2040. North America dominated the market, accounting for the revenue share of 42.3% in 2025. The demand for contrast media is rising owing to the increasing demand for medical imaging and the growing burden of chronic disorders. A high volume of imaging procedures, such as ultrasound and MRI scans, is anticipated to support the market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The growing global demand for medical imaging is a key factor driving the expansion of the contrast media industry. Medical imaging plays a crucial role in the early detection, accurate diagnosis, and effective treatment planning of various health conditions. Millions of patients undergo diagnostic procedures such as MRI, CT scans, and X-rays every year. According to a study published by the National Library of Medicine in October 2023, approximately 40 million MRI scans are performed annually in the U.S. alone. The increasing volume of imaging procedures worldwide is expected to significantly boost the demand for contrast media, essential for enhancing the visualization of internal body structures during these examinations.

To learn more about this report, Download Free Sample Report

Beyond the U.S., other countries are also experiencing a rising demand for medical imaging procedures. According to data published by the Australian Institute of Health & Welfare (AIHW) in July 2024, a total of 10.2 million Australians accessed Medicare-subsidized diagnostic imaging services in 2022-23, while approximately 4.0 million utilized other diagnostic services. This upward trend is expected to continue in the coming years, further contributing to the growing global demand for contrast media used in diagnostic imaging.

To learn more about this report, Download Free Sample Report

Furthermore, the demand for iodinated contrast media is rising significantly, driven by the increasing number of imaging procedures that require enhanced visualization. Several iodinated contrast agents are experiencing strong revenue growth, reflecting increased clinical adoption. For example, in 2024, Bayer AG reported a notable revenue increase from Ultravist, its iopromide-based X-ray contrast agent used for both intra-arterial and intravenous applications. This surge in product demand underscores the expanding utilization of iodinated contrast media in radiology, positioning them as a critical driver of market growth.

To learn more about this report, Download Free Sample Report

The availability of diverse molecular formulations among gadolinium-based and iodinated contrast agents drives market growth. This variety allows for tailored imaging based on patient needs and clinical requirements, enhancing diagnostic accuracy and safety. For instance, gadolinium agents are widely used in MRI, while iodinated agents are suitable for CT. Continued R&D into advanced contrast media with improved safety and efficacy further supports market expansion across diagnostic applications like oncology, cardiology, and neurology.

To learn more about this report, Download Free Sample Report

The pictorial representation below highlights commonly used contrast agents for MRI and CT, along with their respective brand names and molecular compositions.

To learn more about this report, Download Free Sample Report

Source: Grand View Research Analysis

Driver and Restraint Contribution, By Modality

The table below presents the contribution of each driver and restraint for CT and MRI in the U.S., Europe, and China.

Market Dynamics

The market is experiencing steady growth due to the increasing demand for medical imaging and the rising need for accurate and early disease diagnosis. Contrast agents improve the visualization of organs, blood vessels, and abnormal tissues during CT, MRI, and X-ray procedures, supporting the detection and monitoring of cancer, cardiovascular diseases, and neurological disorders. The market is further driven by advancements in imaging technologies, increasing diagnostic screening, and the growing adoption of image-guided procedures. In addition, the development of integrated contrast delivery systems, automated injectors, and digital imaging workflows is expected to improve procedural efficiency and support market growth during the forecast period.

Market Concentration and Characteristics

The market growth stage is high, and the pace of growth is accelerating. The market is characterized by high growth owing to the rising demand for medical imaging, growing launches of novel products, and increasing production capacities for contrast media.

Industry players and researchers are increasingly emphasizing the development of advanced contrast media, with several innovative products currently undergoing clinical trials. For example, in October 2024, GE Healthcare announced encouraging Phase I results for its manganese-based macrocyclic MRI contrast agent. The first-in-human trial demonstrated that the agent was well tolerated, with no severe adverse events, dose-limiting toxicities, or clinically significant findings reported. These positive clinical outcomes are expected to stimulate further innovation and market growth.

To learn more about this report, Download Free Sample Report

“GE Healthcare’s manganese-based contrast agent could offer benefits such as reduced risk of tissue deposition and improved safety for certain vulnerable patient populations compared to gadolinium-based agents, while also providing comparable imaging capabilities and potentially lower environmental impact.” - Said Robert McDonald, radiologist at Mayo Clinic and contrast media safety committee board member for the American College of Radiology.

Regulation of contrast media involves strict oversight to ensure the safety and effectiveness of substances used to enhance medical imaging. Classified as drugs, contrast agents are regulated by authorities such as the U.S. Food and Drug Administration (FDA) and Health Canada, among others. These regulations apply across various imaging modalities, including X-ray, CT, MRI, and ultrasound. In addition, all injectable contrast agents, such as intravenous (IV) formulations, are considered prescription-only medicines (POMs) and are subject to the same regulatory restrictions and controls as other POMs.

Mergers and acquisitions are a key strategic approach in the contrast media industry. They allow companies to broaden their product portfolios, drive innovation, and enhance their market position. Notable players adopting this strategy include Lantheus Holdings, Inc. and Bracco, among others.

Contrast media companies are increasingly focusing on regional expansion to enhance market access and meet the growing demand for contrast agents. A key part of this strategy involves securing marketing authorizations from various regulatory bodies. For example, in September 2022, Guerbet received U.S. FDA approval for Elucirem (gadopiclenol), a gadolinium-based macrocyclic contrast agent (GBCA), for use in contrast-enhanced magnetic resonance imaging (MRI).

Analyst Perspective

The contrast media market is expected to benefit from rising demand for contrast-enhanced diagnostic imaging, expanding access to CT and MRI examinations, and the need for improved visualization in cardiovascular, neurological, gastrointestinal, oncological, renal, and musculoskeletal conditions. Market development also reflects advances in contrast formulations, ultrasound contrast applications, and commercially available non-gadolinium MRI agents. Procurement practices, product availability, administered quantities, and selling prices influence revenue alongside examination volumes. From an analyst’s perspective, companies offering clinically supported products, reliable supply, appropriate regulatory coverage, and competitive procurement terms will be positioned to support adoption. Future market development will depend on formulation innovation, clinical evidence, manufacturing capacity, patient-specific safety considerations, and expansion across hospital and outpatient imaging settings.

Modality Type Insights

The x-ray/computed tomography (CT) segment held the largest revenue share of 69.2% in 2025. The high volume of global CT and X-ray examinations primarily drives this dominant position. For instance, data from the NHS in the UK revealed that in January 2023 alone, Plain Radiography (X-ray) procedures totaled approximately 1.65 million, while Computerized Axial Tomography (CT) scans totaled approximately 0.52 million.

CT imaging plays a critical role in accurately diagnosing a broad spectrum of diseases by offering detailed internal visualization. This modality's effectiveness is enhanced through the use of contrast agents-particularly iodinated and barium-based media- which improve image clarity and diagnostic precision. The wide availability of advanced contrast agents such as Optiray, Omnipaque, and Ultravist further supports the growth of this segment.

The ultrasound segment is projected to grow at the fastest CAGR over the forecast period. This growth is primarily driven by rising investment in the development and production of contrast-enhanced ultrasound (CEUS) products. For instance, in November 2024, Bracco revealed plans to triple the production capacity of its innovative ultrasound contrast agent at its Geneva facility.

This significant investment focuses on scaling up the production of CEUS microbubbles, which are integral to enhancing ultrasound imaging quality. The increasing adoption of CEUS in clinical settings-owing to its safety profile, cost-effectiveness, and ability to provide real-time imaging-is expected to further accelerate segment expansion. As healthcare providers continue to recognize CEUS's diagnostic advantages, the ultrasound segment is well-positioned for substantial growth throughout the forecast period.

Product Insights

The iodinated contrast media segment held the largest revenue share of 64.3% in 2025. This dominance can be attributed to the widespread availability and versatility of iodinated contrast agents, including iohexol, iodixanol, iopamidol, and others. These agents are essential for enhancing the visualization of various anatomical structures, such as the gastrointestinal tract, internal organs, arteries and veins, soft tissues, and the brain.

Iodinated contrast media are used across numerous clinical indications, including neurological, nephrological, gastrointestinal, cardiovascular, musculoskeletal disorders, and oncology. Their broad applicability increases their demand in diagnostic imaging. Furthermore, approvals from regulatory authorities for different applications and modalities support this segment's growth.

For instance, in June 2023, Bayer announced that the U.S. FDA had approved its iodine-based contrast agent Ultravist (iopromide) for use in contrast-enhanced mammography (CEM). Regulatory approvals like these are expected to further fuel the growth of the iodinated contrast media segment in the coming years.

The microbubble contrast media segment is anticipated to grow at the fastest CAGR over the forecast period. Microbubble contrast media are minute bubbles of an injectable gas. They are most often administered for ultrasound imaging of the heart. Contrast agents for ultrasound imaging have been developed to visualize microcirculation in tissue. They enhance the echogenicity of blood and improve the visualization and assessment of tissue vascularity, large vessels, and cardiac cavities. Microbubble contrast media can reflect ultrasound waves, causing structures to appear brighter on ultrasound. Contrast agents for ultrasound imaging can be used in various healthcare settings (CT suite, operating room, echo lab, and others) and are the first-line imaging technique for several indications. Microbubble contrast media is a useful option for patients allergic to CT or MRI contrast media or for patients with kidney failure.

Application Insights

The neurological disorder segment dominated the market with the largest revenue share of 28.3% in 2025. This dominance is attributed to the high prevalence of neurological disorders. According to the data published by the American Brain Foundation in July 2024, over 1 in 3 individuals around the world are affected by neurological conditions. Magnetic Resonance Imaging (MRI) plays a critical role in diagnosing central nervous system (CNS) disorders, offering superior imaging of neural structures compared to other modalities. Gadolinium-based contrast agents (GBCAs), such as OMNISCAN (GE Healthcare), Dotarem (Guerbet), and Prohance, are widely used to enhance diagnostic clarity for evaluation of the CNS. The broad clinical utility and availability of these agents are key drivers of segment growth.

The cardiovascular disorders segment is projected to grow at the fastest CAGR over the forecast period. This growth is primarily driven by the rising global burden of cardiovascular diseases and the increasing use of contrast-enhanced imaging techniques for accurate diagnosis and assessment. Among these, contrast-enhanced ultrasound (CEUS) and echocardiography are among the most widely adopted modalities for imaging the cardiovascular system in adult and pediatric patients.

End Use Insights

The hospital segment led the market with the largest revenue share of 57.5% in 2025. This dominance is primarily driven by the high volume of diagnostic imaging procedures performed in hospital settings, including CT scans, MRIs, and ultrasound examinations, which frequently require contrast agents. Hospitals are typically equipped with advanced imaging infrastructure and staffed by specialized radiologists, making them the primary point of care for complex and emergency cases requiring detailed diagnostic imaging. In addition, the growing number of hospital admissions, expansion of radiology departments, and increasing investments in imaging technology further support the segment's dominance.

To learn more about this report, Download Free Sample Report

The diagnostic imaging centers segment is expected to grow at the fastest CAGR from 2026 to 2040. This growth is driven by the increasing demand for outpatient imaging services, rising healthcare cost-containment efforts, and growing patient preference for quicker, more accessible diagnostic solutions outside hospital settings. Imaging centers often offer shorter wait times, competitive pricing, and specialized services, making them an attractive option for patients and healthcare providers.

Route Of Administration Insights

The intravenous segment held the largest revenue share of 48.1% in 2025. This dominance is primarily attributed to the widespread use of intravenous contrast agents during diagnostic imaging procedures, including CT and MRI. Intravenous contrast delivery enables rapid distribution of the agent throughout the bloodstream, enhancing high-precision visualization of blood vessels, organs, and soft tissues. This segment is also anticipated to grow fastest over the forecast period.

Several contrast agents widely used across hospitals and diagnostic centers, such as Ultravist (iopromide) by Bayer, Visipaque (iodixanol) by GE Healthcare, and Iomeron (iomeprol) by Bracco, are administered intravenously. These agents are commonly indicated for various conditions, including cardiovascular, neurological, gastrointestinal, and oncological disorders. The clinical effectiveness, fast action, and broad applicability of intravenous contrast media continue to drive their preference among healthcare professionals, reinforcing the segment's dominance.

The rectal route segment is projected to grow at the fastest CAGR during the forecast period. This growth is driven by the increasing use of rectally administered contrast agents in gastrointestinal imaging procedures, particularly for evaluating conditions such as colorectal disorders and obstructions. Products like Telebrix Gastro and Micropaque from Guerbet are available for such applications. The effectiveness of this route in enhancing GI visualization and the growing burden of GI disorders are expected to support its increasing adoption in diagnostic practices.

Regional Insights

The North America contrast media marketheld the largest revenue share of 42.3% in 2025. This dominance was driven by the presence of major companies such as GE Healthcare, Bracco S.p.A., Bayer, and Guerbet. In addition, growing approvals of contrast agents by the FDA and Health Canada supported the regional expansion. For example, in March 2024, Lantheus Holdings, Inc. announced that the Health Canada has approved the supplemental new drug application (sNDA) for DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent specifically for use in pediatric patients with suboptimal echocardiograms.

To learn more about this report, Download Free Sample Report

U.S. Contrast Media Market Trends

The contrast media market in the U.S. accounted for the largest market revenue share in North America in 2025, supported by rising diagnostic imaging volumes across CT, MRI, and ultrasound procedures, driven by an aging population and increasing prevalence of cardiovascular diseases, cancer, and neurological disorders. Iodinated contrast media continue to dominate CT imaging due to their widespread use in angiography and interventional procedures, while growing emphasis on patient safety is accelerating the adoption of non-ionic contrast media, which offer improved tolerability and reduced adverse reactions. Technological advancements in imaging systems, increasing use of contrast-enhanced ultrasound, and a shift toward outpatient and ambulatory imaging centers are further shaping market trends, while ongoing innovation focuses on enhancing image quality, safety, and targeted diagnostic applications.

Europe Contrast Media Market Trends

The contrast media market in Europe is expected to experience significant growth, driven by a well-developed healthcare system, rising prevalence of chronic diseases, and increasing demand for advanced diagnostic imaging. Growing incidences of cancer, cardiovascular, and neurological disorders have led to greater reliance on contrast-enhanced imaging procedures such as CT, MRI, and ultrasound. According to the World Health Organization (WHO), by 2030, approximately 5.4 million people are expected to be diagnosed with cancer, and around 2.5 million individuals are projected to die from the disease in the WHO European Region.

The UK contrast media market is expected to grow at a substantial CAGR during the forecast period, driven by increasing demand for diagnostic imaging procedures and the rising prevalence of chronic diseases. A key indicator of this trend is the country's high volume of imaging activity. According to NHS data, approximately 43.4 million imaging tests were performed in England between February 2022 and January 2023. These tests include X-rays, CT scans, MRIs, and ultrasounds, which require using contrast agents to enhance diagnostic accuracy.

The contrast media market in France isexpected to grow rapidly over the forecast period, driven by the rising burden of chronic diseases and the growing strategic focus of industry players on the French healthcare sector. Industry players, such as Bracco, are actively conducting innovative pilot programs in France and Germany to recover residues from gadolinium-based and iodinated contrast agents. These sustainability and recycling initiatives strongly emphasize environmental responsibility and resource optimization. Such efforts align with regulatory priorities and offer companies a competitive advantage in the evolving and environmentally conscious French market.

Asia Pacific Contrast Media Market Trends

The contrast media market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period, driven by a combination of critical factors. Rapidly expanding healthcare infrastructure in emerging economies such as China, India, and Southeast Asia is significantly boosting access to advanced diagnostic imaging technologies. Rising incidence of chronic diseases such as cancer, cardiovascular, and neurological conditions is increasing the demand for accurate and early diagnosis, further fueling the use of contrast agents. According to the International Agency for Research on Cancer (IARC), the number of cancer cases in Australia and New Zealand (ANZ) is projected to rise from 270,155 in 2025 to 298,558 by 2030.

The India contrast media market is anticipated to grow at a lucrative CAGR during the forecast period. This growth is driven by the rising prevalence of chronic diseases, growing demand for advanced diagnostic imaging, and expanding healthcare infrastructure. In addition, increasing awareness about early diagnosis, coupled with government initiatives and private investments in imaging centers, is boosting market growth.

Thecontrast media market in China is driven by a rapidly aging population, increasing prevalence of chronic diseases, and strong government investment in healthcare infrastructure. Rising demand for advanced diagnostic imaging technologies, such as CT and MRI, and expanding access to medical services in urban and rural areas fuel market growth.

Latin America Contrast Media Market Trends

The contrast media market in the Latin America is experiencing steady growth, driven by expanding healthcare infrastructure and rising demand for diagnostic imaging. Countries like Brazil and Argentina are driving the market growth, supported by rising government investment in public health and the adoption of advanced imaging technologies such as CT and MRI. The growing burden of chronic diseases and improved access to healthcare services further boost the use of contrast agents.

Middle East and Africa Contrast Media Market Trends

The contrast media market in the Middle East and Africa is anticipated to grow at a substantial CAGR during the forecast period. This growth is being driven by expanding healthcare infrastructure, particularly in GCC countries and South Africa, alongside increased public and private healthcare spending. The rising prevalence of chronic conditions such as cancer and cardiovascular conditions is boosting demand for advanced diagnostic imaging.

The Saudi Arabia contrast media market is poised for strong growth, driven by public and private healthcare investments and expanding imaging infrastructure. In March 2023, Sajaya Medical Care Services entered a radiology partnership with Bayer International and Scientific and Medical Equipment House, highlighting the region’s emphasis on advanced imaging technologies. Such industry collaborations are expected to support growth in country markets.

Key Contrast Media Company Insights

Bracco S.p.A., Fresenius Kabi USA, LLC, Trivitron Healthcare, Bayer AG, GE Healthcare, Guerbet, iMAX, Lantheus, Beijing Beilu Pharmaceutical Co., Ltd., GRUPO JUSTE, JB Pharma, Jodas Expoim Pvt. Ltd., Livealth, Blue Jet Healthcare, Arco Lifesciences (I) Pvt. Ltd., and Voyageur Pharmaceuticals Ltd. are some major players in the contrast media industry. Companies are expanding their portfolios of contrast media and increasing their production capacities to meet the growing demand. Moreover, industry players are also launching novel agents to gain a competitive advantage.

Key Contrast Media Companies:

The following key companies have been profiled for this study on the global contrast media market.

• Bracco S.p.A.

• Fresenius Kabi USA, LLC

• Trivitron Healthcare

• Bayer AG

• GE Healthcare

• Guerbet

• Beijing Beilu Pharmaceutical Co., Ltd.

• iMAX

• Lantheus Holdings, Inc.

• GRUPO JUSTE

• Voyageur Pharmaceuticals Ltd

• JB Pharma

• Jodas Expoim Pvt. Ltd.

• Livealth

• Blue Jet Healthcare.

• Arco Lifesciences (I) Pvt. Ltd.

Recent Developments

• In January 2025, Bayer reported positive topline results from the Phase III clinical development program for the new MR contrast agent gadoquatrane. These studies assessed the efficacy and safety of gadoquatrane. Gadoquatrane met the main secondary and primary endpoints in these studies.

• In November 2024, Beijing Beilu Pharmaceutical Co., Ltd. received GMP certification from Brazil’s ANVISA for its contrast agent production line. This certification enables the company to enter the Brazilian market successfully and supports further expansion into Brazil and other international markets.

Global Contrast Media Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each sub-segment from 2021 to 2040. For this study, Grand View Research has segmented the global contrast media market report based on product, modality type, application, route of administration, end use, and region:

• Modality Outlook (Revenue, USD Million, 2021 - 2040)

  • Ultrasound

  • Magnetic Resonance Imaging

  • X-ray/Computed Tomography

• Product Outlook (Revenue, USD Million, 2021 - 2040)

  • Microbubble

  • Gadolinium-Based

  • Iodinated

  • Barium-Based

  • Novel Non-gadolinium

• Application Outlook (Revenue, USD Million, 2021 - 2040)

  • Cardiovascular Disorders

  • Neurological Disorders

  • Gastrointestinal Disorders

  • Cancer

  • Nephrological Disorders

  • Musculoskeletal Disorders

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2040)

  • Intravenous

  • Oral Route

  • Rectal Route

• End Use Outlook (Revenue, USD Million, 2021 - 2040)

  • Hospitals

    • Public Hospitals

    • Private Hospitals

  • Diagnostic Imaging Centers

    • Public Diagnostic Imaging Centers

    • Private Diagnostic Imaging Centers

  • Ambulatory Surgery Centers

  • Specialty Clinics & Cath Labs

  • Academic & Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2040)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The contrast media marketfigures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with eachcontrast media segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations